Novartis Tumor Pill Wins European Approval

Novartis AG said its tumor pill Votubia was approved in Europe for a rare brain disease, improving chances that the medicine, which is also used to treat cancers, will become a blockbuster with more than $1 billion in annual sales.
The Wall Street Journal